Inhibitors of Acyl-CoA:Cholesterol Acyltransferase. 4. A Novel Series of Urea ACAT Inhibitors as Potential Hypocholesterolemic Agents

Journal of Medicinal Chemistry

Volumn 36, Issue 22, 1993, Pages 3300-3307

  Trivedi, Bharat K ^a   Holmes, Ann ^a   Stoeber, Terri L ^a   Blankley, C John ^a   Roark, W Howard ^a   Picard, Joseph A ^a   Shaw, Mary K ^a   Essenburg, Arnold D ^a   Stanfield, Richard L ^a   Krause, Brian R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DIFLUOROPHENYL) 1 HEPTYL 1 (4 NEOPENTYLBENZYL)UREA; CHOLESTEROL ACYLTRANSFERASE; ENZYME INHIBITOR; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HYPERCHOLESTEROLEMIA; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTICHOLESTEREMIC AGENTS; CARBANILIDES; STEROL O-ACYLTRANSFERASE; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 0027362917     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00074a011     Document Type: Article

References (35)

1. Trivedi, B. K., Roth, B. US Patent 5,015,644; 1991.
2. Norum, K. R.; Lillijeqvist, A.-C.; Helgerud, P.; Normann, E. R.; Mo, A.; Selbekk, B. Esterification of Cholesterol in Human Small Intestine: The Importance of Acyl-CoA:cholesterol Acyltransferase. Eur. J. Clin. Invest. 1979, 9, 55–62.
3. Suckling, K. E.; Stange, E. F. Role of Acyl-CoA:cholesterol Acyltransferase in Cellular Cholesterol Metabolism. J. Lipid. Res. 1985, 26, 647–671.
4. Krause, B. R.; Newton, R. S. ACAT Inhibitors: Preclinical Pharmacologic Profiles and Implications for Plasma Lipid Regulation and Prevention of Atherosclerosis. In Atherosclerosis VIII; Crepaldi, G., et al., Eds.; Elsevier Scientific Publication: Amsterdam, 1989, 707–710.
5. Sliskovic, D. R.; White, A. D. Therapeutic Potential of ACAT Inhibitors as Lipid Lowering and Antiatherosclerotic Agents. Trends Pharmacol. Sci. 1991, 11, 194–199.
6. Heider, J. G.; Pickens, C. E.; Kelly, L. A. Role of Acyl CoA: Cholesterol Acyltransferase in Cholesterol Absorption and its Inhibition by 57–118 in the Rabbit. J. Lipid Res. 1983, 24, 1127–1134.
7. Albright, J. D.; DeVries, V. G.; Largis, E. E.; et al. Potential Antiatherosclerotic Agents. 2. (Aralkylamino)- and (Alkylamino)-benzoic Acid Analogues of Cetaben. J. Med. Chem. 1983, 26, 1378–1393.
8. Albright, J. D.; DeVries, V. G.; Du, M. T.; et al. Potential Antiatherosclerotic Agents. 3. Substituted Benzoic and Nonbenzoic Acid Analogues of Cetaben. J. Med. Chem. 1983, 26, 1393–1411.
9. DeVries, V. G.; Largis, E. E.; Miner, T. G.; Shepherd, R. G.; Upeslacis, J. Potential Antiatherosclerotic Agents. 4. [(Functionalized-alkyDamino] benzoic Acid Analogues of Cetaben. J. Med. Chem. 1983, 26, 1411–1421.
10. DeVries, V. G.; Schaffer, S. A.; Largis, E. E.; et al. Potential Antiatherosclerotic Agents. 5. An Acyl-CoA: Cholesterol O-Acyltransferase Inhibitor with Hypocholesterolemic Activity. J. Med. Chem. 1986, 29, 1131–1133.
11. Natori, K.; Okazaki, Y.; Nakajima, T.; Hirohashi, T.; Aono, S. Mechanism of the Inhibition of Cholesterol Absorption by DL-Melinamide: Inhibition of Cholesterol Esterification. Jpn. J. Pharmacol. 1986, 42, 517–523.
12. Schnitzer-Polokoff, R.; Compton, D.; Boykow, G.; Davis, H.; Burner, R. Effects of Acyl-CoA: cholesterol Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters. Comp. Biochem. Physiol. 1991, 99A, 665–670.
13. Largis, E. E.; Wang, C. H.; DeVries, V. G.; Schaffer, S. A. CL277,082: A Novel Inhibitor of ACAT-Catalyzed Cholesterol Esterification and Cholesterol Absorption. J. Lipid Res. 1989, 30, 681–690.
14. DeVries, V. G.; Bloom, J. D.; Dutia, M. D.; Katocs, A. S. Jr.; Largis, E. E. Potential Antiatherosclerotic Agents. 6. Hypocholesterolemic Trisubstituted Urea Analogues. J. Med. Chem. 1989, 32, 2318–2325.
15. Balasubramanian, S.; Simons, L. A.; Chang, S.; Roach, P. D.; Nestel, P. J. On the Mechanism by Which an ACAT Inhibitor (CL 277,082) Influences Plasma Lipoproteins in the Rat. Atherosclerosis 1990, 82, 1–5.
16. Larsen, S. D.; Spilman, C. H.; Bell, F. P.; et al. Synthesis and Hypocholesterolemic Activity of 6,7-Dihydro-4H-pyrazolo[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-diones, Novel Inhibitors of Acyl CoA: Cholesterol O-Acyltransferase. J. Med. Chem. 1991, 34, 1721–1727.
17. Harnett, K. M.; Walsh, C. T.; Zhang, L. Effects of Bay o 2752, A Hypocholesterolemic Agent, on Intestinal Taurocholate Absorption and Cholesterol Esterification. J. Pharm. Exp. Ther. 1989, 251, 502–509.
18. Windler, E.; Rucker, W.; Greeve, J.; Reimitz, H.; Greten, H. Influence of the Acyl-coenzyme Axholesterol-acyltransferase Inhibitor Octimibate on Cholesterol Transport in Rat Mesenteric Lymph. Arzneim.-Forsch. 1990, 40, 1108–1111.
19. Heffron, F.; Middleton, B.; and White, D. A. Inhibition of acyl coenzyme A:cholesterol acyltransferase by trimethylcyclohezanylmandelate (cyclandelate). Biochem. Pharm. 1990, 39, 575–580.
20. For a review see: O'Brien, P. M.; Sliskovic D. R. Current Drugs 1992, 507.
21. Roth, B. D.; Blankley, C. J.; Hoefle, M. L.; Holmes, A.; Roark, W. H.; Trivedi, B. K.; Essenburg A. D.; Kieft, K. A.; Krause, B. R.; Stanfield, R. L. Inhibitors of Acyl-CoA: Cholesterol Acyltransferase. I. Identification and Structure-Activity Relationships of a Novel Series of Fatty Acid Anilide Hypocholesterolemic Agents. J. Med. Chem. 1992, 35, 1609–1617.
22. Krause, B. R.; Anderson, M.; Bisgaier, C. L.; Bocan, T.; Bousley, R.; DeHart, P.; Essenburg, A.; Hamelehle, K.; Homan, R.; Kieft, K.; McNally, W.; Stanfield, R.; Newton, R. S. In Vivo Evidence That the Lipid Regulatory Activity of the ACAT Inhibitor CI-976 in Rats is Due to Inhibition of Both Intestinal and Liver ACAT. J. Lipid. Res. 1993, 34, 279–294.
23. Bocan, T. M. A.; Mueller, S. B.; Ohlendorf, P. D.; Newton, R. S.; Krause, B. R. Comparison of CI-976, an ACAT Inhibitor and Selected Lipid Lowering Agents for Antiatherosclerotic Activity in Iliac-Femoral and Thoracic Aortic Lesions: A Biochemical, Morphological, and Morphometric Evaluation. Arteriosclerosis Thrombosis 1991, 11, 1830–1843.
24. Roark, W. H.; Holmes, A.; Trivedi, B. K.; Roth, B. D.; Essenburg, A. D.; Kieft, K.; Stanfield, R. L.; Krause, B. R. Inhibitors of Acyl-CoA:Cholesterol Acyltransferase (ACAT). 2. Modification of Fatty Acid Anilide ACAT Inhibitors: Bioisosteric Replacement of the Amide Bond. J. Med. Chem. 1993, 36, 1662–1668.
25. Trivedi, B. K.; Stoeber, T. L.; Stanfield, R. L.; Essenburg, A. D.; Hamelehle, K. L.; Krause, B. R. Substituted N,N′-Diphenyl Ureas as Potent Inhibitors of Acyl-CoA:Cholesterol Acyltransferase (ACAT). Bioorg. Med. Chem. Lett. 1993, 3, 259–262.
26. McKillop, A.; Tarbin, J. A. Functional Group Oxidation Using Sodium Perborate. Tetrahedron 1987, 43, 1753–1758.
27. DuBois G. E.; Stephensen R. A. Sulfonylamine Mediated Sulfamation of Amines. A Mild, High Yield Synthesis of Sulfamic Acid Salts. J. Org. Chem 1980, 45, 5371–5373;
28. DuBois G. E. Amination of Aryl Sulfamate Esters. A Convenient General Synthesis of Aliphatic Sulfamides. J. Org. Chem. 1980, 45, 5373–5375.
29. Peterson, H. J.; Nielsen, C. K.; Arrigoni-Martelli, E. Synthesis and Hypotensive Activity of N-alkyl-N″-Cyano-N′-Pyridylguanidines. J. Med. Chem. 1978, 21, 773.
30. 2 Receptors. J. Med. Chem. 1982, 24, 913–920.
31. 2 Receptor Antagonist Activity for Cimetidine Analogs. J. Med. Chem. 1986, 29, 44–49.
32. Charton, M. The Prediction of Chemical Liability Through Substituent Effects In Design of Biopharmaceutical Properties through Prodrugs and Analogs; Roche, E. B., Ed.; American Pharmaceutical Association: Washington, D. C., 1977; pp 228–280.
33. Hansch, C.; Leo, A. Substituent Constants For Correlation Analysis in Chemistry and Biology; Wiley & Sons: New York, 1979.
34. Fujita, T.; Nishioka, T. The Analysis of the Ortho Effect. Prog. Phys. Org. Chem. 1976, 12, 49–89.
35. Blankley, C. J. Manuscript in preparation.